A
ABH histo-blood group antigens 422
Accessory cholera enterotoxin 383
Accredited social health activists 550
Achievement of GVAP goals 549
Active and passive immunization 508
Acute
disseminated encephalomyelitis 367
gastroenteritis with vomiting 422
hypersensitivity reaction 85t
illness 257
neurologic phase 376
respiratory tract infections 586
toxin mediated bacterial infection 174
toxin mediated disease 174
viral infection 284
Adaptive immune systems 507
Adequate titer of antibody 38
Administration of the vaccine to seroconversion 485
Adverse drug reaction 582
AEFI causality assessment 86
Aerophobia 376
Age of immunization 590
AIDS: a clinical syndrome 455
Alleviation of pain associated with injections 53
Allied vaccine group 603t
Alum-adjuvanted gpE1 glycoprotein 445
Aluminium salt adjuvants 126
Alzheimer’s disease 406
American Health Organization 576
Analytical testing 545
Anaphylactoid reaction 85t
Angioimmunoblastic lymphadenopathy lesions 435
Antenatal tetanus vaccination 214
Anterior nasal diphtheria 176
Antibiotic resistance 224
Antibody
containing product 60
dependent cell-mediated cytotoxicity 39
vaccine interactions principles of 59
AntigpE1/gpE2 446
Anti-hypertensive vaccine 407
Anti-idiotype vaccines 403
Antimeasles antibodies 268
Antimicrobials and antimicrobial resistance 310
Anti-nicotine antibodies 406
Antirabies vaccines 378
Antiseptics 377
Apical membrane antigen-1 464
Aplastic anemia 291t
Appraisal of national vaccine policy 535
Argentinian hemorrhagic fever 387
Artemisinin combination therapy (ACT) for treatment 461
Arthritis 291t
Aseptic meningitis 284
Associated malpractices 600
Assuring vaccines of quality and safety 105
Astroviruses 249
Autologous
EBV CTLs 435
hematopoietic stem cell transplants 507
tolerizing dendritic cell vaccine 406
Autonomic changes 186
Avian H5N1 influenza 344
B
B lymphocytes and antibodies 38
Barriers for adolescent vaccination 520
Basics of immune system and vaccination 507
BCG
against primary infection 141
laboratory in guindy 14
revaccination strategies 142
vaccine correlate for protection afforded 41
Bioadhesive delivery system 491
Biodegradable polymers 486
Bolivian hemorrhagic fever 387
Boolean operators 604
Booster doses 59
Bovine-human reassortants 253
Brachial neuritis 85t
British Medical Journal 605
Broader framework means for India 568
C
Campylobacter jejuni 423
Canadian Coalition for Immunization Awareness and Promotion 108
Canadian International Development Agency 281
Capacity building 545
Capsomers 433
Capsular strains 222
Carbohydrate vaccines 403
Carboxyfluorescein succinimidyl ester 40
Carcinoembryonic antigen 402
Case definition of
chikungunya virus 469
malaria 461
neonatal tetanus 111
severe malaria 461
the rotavirus vaccine 103
typhoid fever 308
vaccine-associated paralytic poliomyelitis 587
Catch-up
vaccination schedule for an unimmunized child 62t
Causality assessment of serious AEFI 87f
Causation of diseases 45
Causative agent of cervical carcinoma 402
Causes of
malpractice in vaccine marketing 600
pneumonia 222
respiratory tract infections 472
viral lower respiratory tract infection 473
CD4+ helper T cells 38
CD8 cells 33
Cells of the innate immune system 122
Central Drugs Standard Control Organization 581
Cephalic tetanus 185
Cerebellar ataxia 284
Cervical intraepithelial neoplasia 335
Cetrimide solution 377
CFSE-labeling assay 40
Chickenpox 323
Childhood immunization support program 108
Children with asplenia/hyposplenia 54
Children’s hospital of Philadelphia 603t
Chimeric vaccine 369
Chlorhexidine gluconate 377
Chloroxylenol 377
Cholera
epidemiology and risk factors 423
Chronic hepatitis C infection 439
Circumsporozoite protein 462
Cleavage of opinion 588
Clinical
and epidemiological features of polio virus infection 148
features of malaria 461
manifestations of hepatitis A virus infection 290
picture of typhoid fever 307
studies of vaccine 324
trials registry-India 582
Cocooning strategy 206
Cohort study 49
Coincidental 80
Coley’s toxins 401
Collective decision-making 281
Colonization factor antigens 426
Combination of
hepatitis A and B vaccine 170
measles-mumps-rubella-varicella 60
vaccines including multiple life cycle stages 464
blood stage antigens 464
Commercially available vaccines 337t
Communicable diseases 588
Community health center 90f
Community-based immunization programs 589
Company medical representative educated 598
Comparison of
hepatitis A virus infection 291
India’s vaccination coverage 565f
inoculation and vaccination 11t
vaccination coverage within india 565f
Components of national vaccine policy 534
Composition of the vaccine 336
Comprehensive multi-year plans 574
Compulsory immunization 589
Concurrent administration with other vaccines 337
Conditioning of ice packs 96
Conflict of interest 579
Conjugate vaccines 476
Consensus recommendations on immunization 597
Contact immunity 75
Contingency plans 98
Continuous medical education 598
Control of muscle rigidity and spasms 188
Corresponding polysaccharide vaccine 360
Cost
and affordability 586
and sustainability 560
benefit of varicella vaccine 326
effectiveness analysis 567
imulatory molecules 404
Council of Medical Research 576
Coverage estimate series 101t
Crimean Congo hemorrhagic fever 387
Cutaneous diphtheria 176
Cytokine release assays 40
D
Dangerous diseases 521
Deaths and disability-adjusted life years 262
Defensins 261
Defining search terms 604
Delayed type hypersensitivity 39
Democratic Republic of the Congo 282
Dengue
immunity 417
no vaccine to protect against 417
vaccine development 418
vaccines first and second generation 420
virions 418
virus 386
Department of Biotechnology 539
Department of Health Research 579
Dermatitis 291t
Detective ovine at adenovirus expressing NS3 445
Diarrheal disease vaccines 421
Different inactivated hepatitis A virus 296t
Dioxygenase 402
Diphtheria
morbidity 175
Direct negative impact 78
Disclosure statements 547
Disease burden 292
Diseases of
elimination and eradication 110
management 516
pattern 293
the most impoverished program 304f
the neighborhood 317
transmission
basic reproductive rate 45
epidemic threshold 45
index case 45
infection rate 45
net reproductive rate 45
primary case 45
secondary attack rate 45
Disposal of auto-disable syringes 106
Disseminated BCG infection 85t
District Immunization Officer 85
District Level Household and Facility Survey-3 271
Documentation 591
Domestic refrigerator 92
Dosage of routine vaccination 167
DPT vaccines 214
Dracunculiasis 115
Dracunculus medinensis 115
Droplet precautions 358
Drug Controller General of India 581
DTaP vaccines 220
DTwP 394
E
Easles vaccine 5
Echovirus serotypes 412
Edible vaccines 493
Edmonston-zagreb strain 265
Edward Jenner’s observations 12
Effect of varicella vaccine 326
Effectiveness of varicella vaccine 325
Efficacy of
DTP 220
effectiveness of Hib conjugate vaccines 232f
HAV vaccines 298
modern IPV 150
tOPV 159
Electrical cold chain equipment 91
Electroencephalogram 366
Elimination of
disease 113
infections 113
measles, rubella, and maternal and neonatal tetanus 23
neonatal tetanus 118
ELIspot 36
Encephalitis virus 386
Encephalopathy 85t
Encodes six structural viral proteins 250
Endemic cholera 385
Endemic meningococcal disease 361
Endemicity 293
End-stage kidney disease 130
Enteric encephalopathy 366
Enterovirus (EV)
classification of 411
infections
clinical spectrum of 412
epidemiology 412
laboratory diagnosis 413
management 414
vaccines 411
Enveloped ribonucleic acid 386
Epidemiology of
chikungunya virus 469
hepatitis A virus infection 291
human papillomavirus 335
malaria 461
relation to vaccinology 43
respiratory syncytial virus infections 472
typhoid fever 304
varicella 326
Epidermal powder immunization 492
Epithelial-mesenchymal transition 405
Equine rabies immunoglobulin 377
Eradicability of a disease 112
Eradication and comprehensive health programs 114
Eradication of
malaria 460
polio in India 71
poliomyelitis 550
small pox 214
source of toxin 187
vaccine 549
Estimated global disease burden of typhoid fever 304f
ETEC vaccine approaches 427
Etiological diagnosis 366
Exanthems and enanthems 412
Exosomes 490
Expansion beyond Africa 281
Expiry date of vaccines 591
Eyes of conjunctivitis patients 222
F
Failure of acellular pertussis vaccines 205
Family flaviviridae 386
Fatal rotavirus diarrhea 250
Febrile seizures 85t
Financial resources for immunization 548
First dose of BCG 141
First vaccine was administered in India 10
Flaviviral infection 417
Flexibility 586
Follicular dendritic cells 485
Fourth-generation IPV 152
Framingham heart study 49
Freer 579
Freeze-tolerant vaccines 94
Funding and remunerations 581
Fusion protein 437
G
Gamma glutamyl transferase 291
Gastric carcinoma 435
Gene-based vectors 473
General mode of action (MoA) of adjuvants 126f
Genetic
changes 196
modification of T cell receptors (TCRs) 435
reassortment 342
susceptibility 405
vaccination 546
Genomes of certain viruses 404
Genus lymphocryptovirus 433
Glatiramer acetate 405
Global Polio Eradication Initiative 117
Global vaccine market 533
Government medical store dipots 90f
Gram-negative coccobacillus 196
Gram-positive enhancer matrix 490
Granulocyte-macrophage colonystimulating factor 403
Granzyme 38
Graphical depiction of heat and freeze sensitivities 92f
Guidelines for manufacture of vaccines 102
Guidelines for typhoid threshold responses 310t
Guinea pigs 588
GW diseases 115
H
H1N1 virus 344
H5N1 viruses 345
Health and child care personnels 327
Healthcare professionals 599
Healthcare providers 352
Heat and light sensitive vaccines 91t
Heat shock protein (HSP)-based vaccines 403
Hemagglutination assay 388
Hematopoietic stem cell transplant 508
Hemolysin 383
Hemorrhagic viral fever 387
Hep A or typhoid combined vaccine 395
Hep B and hep A combined vaccine 395
Hepatitis C virus (HCV)
infections 296
epidemiology 441
immune invasive response 441
natural history of 440
pathogenesis 440
rationale for a therapeutic 442
strategies for 442
vaccine approach 441
Hepatitis E virus (HEV) 448
Hepatitis E virus like particles 450
Hepatocellular carcinoma 439
Hepatovirus genus 290
Herpangina 413
Heteroclitic modifications 403
Hib
attributable proportion 226
meningitis 224
pneumonia 224
polysaccharide antigen 224
polysaccharide vaccine 227
vaccine 48
High-grade squamous intraepithelial lesion 335
H-influenzae B 78
Historical background of malaria 462
HIV 142
Hold over time 95
Host cell ribonucleic acid 546
Human
animal reassortant vaccines 252
bovine chimeric viruses 474
caliciviruses 422
carcinogens 164
embryonic lung cells 324
enterovirus 71
vaccine 414
immune
system 507
virus 105
immunodeficiency virus 1
genome 455f
infection 549
vaccine 454
mucous membrane 175
parainfluenza virus vaccines 473
rabies immunoglobulin 377
respiratory syncytial virus 473
rotavirus strain vaccines 253
to-human transmission 379
Hydrophobia 376
Hyperimmune immunoglobulin 462
Hypersensitivity reactions 388
Hypertension 407
Hypocalcemia 187
I
Ideal storage method 94
IgG antibodies against measles 269
Immune
correlates of protection 200
evasion strategies by Epstein-Barr virus (EBV) 436
individuals 77
memory 70
reconstitution 508
response to
pathogen 124f
primary 29
secondary 31
suppression in the tumor microenvironment 402
system 106
Immunity duration of 270
Immunization
advisory centre 108
certificate 593
coverage in India 564f
cross-pathy 592
during travel 592
for travelers 505
general recommendations on 52
in the context of global interdependence 554
of HIV infected children 504t
of immunocompromized people 603
practices advisory committee 574
practices in childhood 590
program 520
purpose of 57
safety 105
schedule 57
successes 551
technical support unit 579
timetable recommended by Indian Academy of Pediatrics 61t
Immunoenhancing molecules 128
Immunogenic determinants of LMP1 437
Immunological
correlates of protection induced by vaccines 37
hyporesponsiveness 361
issues in patients 512
principle 59
responsiveness 58
Immunoprophylaxis 64
Immunostimulatory 484
Impact and incidence of vaccine preventable disease 522f
Implications for manufacturing 545
Importance of maintaining the cold chain 90
Incidence of communicable diseases 78
Increase cool mass 93
Incubation period 376
India’s national guinea worm eradication program 116
Indian national technical advisory group on immunization 271
Indian neonatal strain vaccine 253
Indian technical advisory group on measles mortality reduction 578
Indirect negative impact 78
Indirect or herd protection 262
Infectious agent
antigenic stability and survival 46
immunogenicity 46
infectivity 46
pathogenicity 46
virulence 46
Infectious mononucleosis 434
Infective polyneuritis 291t
Inflammatory diseases 511
Influence of radiation therapy 511
Influenza
A viruses 341
clinical management and treatment 346
clinical signs and symptoms 346
complications 343t
diagnosis 346
epidemics and pandemics 342
H9N2 viruses 345
immunization of pregnant women 352
outbreaks 342
pandemics 342
prevention 347
seasonality 345
choice of 350
licensed in india 352t
viruses
characteristics of 342t
from different species 341
infection 352
Information, education, and communication 20
Informed consent 590
Inhibiting CD4 34
Inhibitors of influenza 346
Injectable poliovirus vaccine 53
Injection
procedure
site and needle length 53
sterile technique 52
reaction 82
safety and waste disposal 19
site
abscess 85t
type of needle and technique 54t
Injiang uighur autonomous region 448
Innovative route of vaccination 67
Inoperable cancers 401
Institute for vaccine safety 108
Integrated disease surveillance program 51
Intellectual property rights and vaccines 553
Intensification of routine immunization 22
Intensity of primary humoral response 31
Intensive care unit 592
Interferon alpha 405
Intermediate endemicity 293
International Pediatric Association 282
International Task Force for Disease Eradication 111
Interval between doses 59
Intracellular cytokine detection 40
Intradermal rabies vaccination 380
Intramuscular injections 54
Intravenous immunoglobulin 388
Intussusception monitoring 262
Invalid contraindications to immunization 105
Invariant natural killer T cells 41
L
Lack of exposure variation 104
Lactic acid bacteria 490
Lapsed immunization 505
Lassa fever 387
Legal issues in immunization 588
Length of protection 141
Leptospirosis 387
Lethal midline granuloma 435
Life cycle of the parasite 115
Lipopolysaccharide 486
Live
attenuated influenza vaccine 349
efficacy 350
safety 349
transmissibility of 350
influenza vaccine 348
injectable vaccine 60
oral Ty21a vaccine 312
oral vaccines 427
recombinant vaccines 456
Liver cancers 404
Localized tetanus 185
Low birth rate infants 169
Low endemicity 293
Low-grade squamous intraepithelial lesion 335
Lymphadenitis 85t
Lymphoproliferative disease 435
Lyssavirus 375
M
Magic bullet 588
Maintenance of the vaccine refrigerator 94
Malaria vaccines 460
Management of AEFI 82
Mandatory adolescent vaccines 519
Manifestations of severe malaria 461t
Mannose-binding lectin 26
Manufacturing basics 544t
Marburg and Ebola fever 387
Market fluctuation in stocks 561
Marketing of vaccines 599
Maximum stock level 97
Maximum-minimum inventory control system 97
Measles 517
Measles
and MMR vaccine 525
and rubella initiative 279
cases global 266
containing vaccine 563
diagnosis of 267
diphtheria, pertussis 520
epidemiology of 267
initiative 279
mumps-rubella-varicella 329
vaccination coverage 267
Mechanisms of antibody-mediated vaccine immunity 38
Melanoma antigen-1 402
Melanomas 404
Meningeal and miliary tuberculosis 141
Meningitis 226
Meningococcus serogroup 358
Method of disposal 106t
Methods of delivering transcutaneous vaccine 493
MHC tetramer assays 40
Minimum stock level 97
Minor genetic reversion 154
Misconceptions about
vaccine safety 106
Misinformation about vaccine safety 106
Monophosphoryl lipid 486
Monovalent human G1 rotavirus vaccine 253
Mortality associated with pertussis 194
Multidose vials 53
Multiple
epitope constructs 463
HCV gene products 446
puncture technique 140
vaccines 522
vesicular lesions on the palm in HFMD 413
Multiplex bead arrays 40
Murray valley encephalitis virus 386
Mycobacterium leprae 25
Mycobacterium tuberculosis 393
Myocarditis 413
N
Nasal lymphomas of T cell 435
National Center for Immunization and Respiratory Diseases 108
National Center for Disease Control 51
National Child Survival 118
National Committees on Immunization Practices 574
National Control Laboratories 582
National Health Service 602
National Immunization Programs 563
National Immunization Schedule 563
National Immunization Technical Advisory Groups 538t
National Institute of Immunology 539
National Library of Medicine 604
National Network for Immunization Information 603t
National Pertussis Immunization Policy 208
National Schedules for Hib Conjugate Vaccines 234t
National Tuberculosis Control Program 15
Neisseria meningitidis 357
Neuraminidase 341
Neuritis 176
Neutralization of unbound toxin 187
New England Journal of Medicine 605
New pertussis vaccine approaches 207
New technologies for vaccine development 475
New thinking on health and wealth 566
New vaccine into an immunization program 556
New-generation vaccines 311
NGO organize camps 596
Non-communicable diseases 588
Non-enveloped ribonucleic acid (RNA) virus 448
Nonexperimental study 49
Nonimmune prevaccination 368
Noninfectious diseases 113
Nonlife-threatening diseases 520
Novel
development strategies 66
influenza viruses in humans 342f
reassortant virus 341
sub-committees 578
NTAGI work-up recommendation 580
Nucleic acids 414
Nucleotide back-mutation 154
Number of immunogenic proteins 107t
Numbered enterovirus serotypes 412
O
Obstacles in the development of HIV vaccine 456t
Obstacles in the vaccine development 472
Ocular infections 413
Oncofetal antigens 402
Online search for articles 604
Operational feasibility 561
Opsonization 26
Optimal immunization coverage 548
Optional immunization 589
Orthomyxoviridae family 341
Osteitis 85t
Osteomyelitis 85t
P
Packing of vaccine carrier 97
Pandemic H1N1 influenza 344
Pandemics of influenza 344
Parainfluenza virus vaccines 472
Paramyxoviridae 284
Paranasal sinuses 241
Particulate delivery systems 478
Pathogenesis of
associated molecular patterns 26
hepatitis A virus infection 291
life cycles 116f
related barriers 473
respiratory syncytial virus infections 472
typhoid fever 306
Patient’s immune system 507
Pediatrician must 596
Pentavalent WC3-based bovine-human reassortant vaccine 253
Peptidoglycans 26
Perinatal transmission 163
Peripheral T cell lymphomas 435
Persistence of antibodies 297
Pertusis and tetanus 58
Petechiae and purpura 412
Phagocytosis 406
Pharmaceutical industries 599
Pharyngeal and tonsillar diphtheria 176
Phases of vaccine trials 102
Picornaviridae 412
Placebo groups 405
Placement of refrigerator 93
Plasmid DNA vaccines 546
Pneumococcal
conjugate vaccines
cost effectiveness 245
dosing schedules 245
effectiveness 244
efficacy of 244t
recommendations for use 246
safety 245
serotype replacement 245
disease and rotavirus 563
pneumonia 241
polysaccharide vaccine (PPSV 23) 60
epidemiology 241
pathogenesis 240
pneumococcal vaccines 242
serotype distribution 242
Pneumococcus 561
Pneumonia and meningitis case definitions 223
Polio and measles 563
Polio and rotavirus (RV) 58
Politician/Officer Vaccinate 596
Polylactic-co-glycolides acid 486
Polysaccharide
antigens 29
conjugate vaccines 428
contained in vaccines 107t
selected serotypes of pneumococcus 240
vaccine in developing countries 313t
Poor immunogenicity 501
Post-infectious encephalitis and vitamin A deficiency 266
Postlicensure evaluation of vaccine safety 103
Postmarketing studies 103
Postvaccination seroconversion 367
Potential vectors for live recombinant vaccine 457t
Power failure 95
Pregnancy 327
Prelicensure evaluation of vaccine safety 101
PreP vaccination schedule 381
Preventive maintenance of vaccine refrigerator 94t
Primary
bacteremia 306
health center 90f
humoral response, persistence of 31
immunodeficiency patients 507
Prime-boost concept 458
Priming of humoral and cellular (CD4 and CD8) immune responses 446
Principal indicators of eradicability 113
Principles of good manufacturing practices 105
Private sector and vaccination 21
Probable meningitis 230
Prodrome 376
Program errors leading to adverse events 81t
Program implementation and monitoring 535
Progressive rubella panencephalitis 273
Prolonged cholestatic phase 291t
Prostatic carcinomas 404
Protective antibody levels 39t
Protein-based vaccines 403
Provincial disease burden in Vietnam 304f
Pseudomembrane formation 174
Pulmonary tuberculosis 141
Purpose-built refrigerator 95f
Purulent discharge 222
Pyogenic meningitis 366
Pyothorax associated lymphoma 435
Q
Quadrivalent
meningococcal polysaccharide vaccines 361
RRV-based rhesus-human reassortant vaccine 252
vaccine 363
Quality of the immune response 402
R
Radiolucent bone disease 274
Rapid fluorescent focus inhibition test 378
Rational antigen discovery 479
Reaching every community 589
Reactogenicity of diphtheria toxoid 181
Recognize individual vaccine refrigerator 93
Recombinant
human immunodeficiency virus 457t
subunit human immunodeficiency virus 458t
vaccines 477
varicella-zoster virus 436
Recurrent disease 330
Red blood cells 463
Refrigerator before stocking 93
Regional elimination 113
Regulatory T-cells 402
Relapsing hepatitis 291t
Releasing antimicrobial cytokines 36
Reliable
information regarding immunization 602
resources on vaccines and immunization practices 603t
Replicons and DNA plasmids 473
Research and development 539
Retrospective study 50
Review Committee on Genetic Manipulation 582
Rhabdoviridae 375
Rhesus rotavirus vaccine 481
Rickettsia 387
Rift valley fever 387
Risk factors for typhoid fever 305
Risk of transmitting human immunodeficiency virus 296
Role of
academic organizations 597
hepatitis B immune globulin 171
national technical advisory group for immunization 572
of government 597
of immunization 79
pediatrician in office practice 88
pharmaceutical industry 596
society 597
the innate immune response 133
the provider 104
RotarixTM (GSK biologicals)
coadministration with other vaccines 254
immunogenicity in India 254
preterm infants 257
spitting or regurgitation 256
Rotavirus
classification of 250
disease burden 250
epidemiology 250
age distribution 251
burden of disease 251
clinical features 251
pathogenesis 252
strain distribution 251
transmission 250
example 481
structure and classification 250
vaccination in the developing world 260t
vaccine development 252
vaccine introduction 259
Route of administration 297
Routine postvaccination testing 171
Routine vaccination 524
RV3 neonatal strain vaccine 253
S
Safeguard the power source 93
Safety of
adjuvanted licensed vaccines 132
assessment 132
biovac A 298
evaluation of vaccines 131f
modern IPV 150
Scientific feasibility 112
Scope of a vaccine policy 534
Secretory antibodies 69
Selection of the appropriate antigen 123
Semliki forest virus expressing NS3 445
Sensitivities of vaccines to heat and cold 91f
Sensorineural hearing loss 284
Sepsis 85t
Serologic testing 506
Serum of
bactericidal activity 361
glutamate pyruvate transaminase 291
glutamic-oxaloacetic transaminase 291
vaccination 563
vibriocidal antibodies 383
Sexually transmitted disease 335
Shifting endemicity of hepatitis A virus 293f
Shigella vaccines 429
Shigellosis 427
Simian immunodeficient virus 456
Simultaneous vaccines 393
Single dose
effectiveness in argentina 301
of inactivated HAV vaccine 300
short-term efficacy 301
tetanus toxoid 485
Skeletal muscle paralysis 156
Skin sensitivity test 377
Skin-associated lymphoid tissue 493
Smallpox eradication from india 15
Smooth muscle cell tumor 435
Sociopolitical and economic factors 572
Solid organ transplantation 512
Southeast Asia region 279
Specific issues related to immunization 592
Spectrum of disease control 111
Spontaneous reporting systems 103
St Louis encephalitis virus 386
Stabilize the temperature 93
State expanded program on immunization officer 86
Status of pertussis 194
Stem cell transplants 507
Steps in vaccine manufacturing 545
Stomach flu 422
Strains of pneumococci 241
Streptococcus mutants surface protein antigen A 450
Streptococcus pneumoniae 240
Subacute sclerosing pan-encephalitis 265
Suboptimal vaccine coverage 214
Supplementary immunization activity 265
Supporting Independent Immunization and Vaccine Advisory Committees 576
Supportive intensive care 188
Supratentorial involvement 284
T
Tackle vaccine challenges 123
TB vaccines 144t
Tdap vaccine 219
Technology of microneedle-based vaccine 493
Tetanus
and diphtheria toxoids 517
bacilli 184
control 183
immunoglobulin 50
prevention 183
toxoid
containing vaccine 53
immunization 532
injection 377
Thalassemia diseases 592
The Plan Builds on the Global Polio Eradication Initiative 282
The United Nations Children’s Fund 279
T-helper cells 26
Thrombospodin-related adhesion protein 463
Tips for better vaccine storage 93
Tobacco addiction 406
Tonsillar and laryngeal regions 174
Topical lidocaine-prilocaine emulsion 53
Total leukocyte count 455
Transforming growth factor-β 402
Transmembrane ion channel 346
Transmission of vaccine type virus 324
Transportation of a vaccine 90f
Transverse myelitis 284
Traveler’s risk of
adolescent vaccines 519
cholera 527
Japanese encephalitis 527
rabies 527
typhoid fever 527
vaccinators 12
yellow fever 525
Tremendous impact on morbidity 214
Tripolyphosphate 491
True adolescent vaccines 518
Tuberculosis, tetanus, diphtheria 516
Ty21a vaccine in developing countries 312t
Tyrosinase 402
U
Ubiquitous distribution of tetanus spores 192
Ulcers on the oral mucosa in HFMD 413f
Under trial vaccines 588
Uniform resource locaters 606
United Nations Children’s Fund 312
Universal Immunization Program Schedule in India 21t
Universal immunization Program in India 17
Upper respiratory infection 324
V
Vaccination
against malaria 546
aim of 48
by intradermal route 169
containment 48
control 48
document 524
during
an acute illness 53
lactation 52
pregnancy 52
elimination 48
eradication 48
extinction 48
HIV infected children 502
in India 9t
information statements 588
issues 514
new immigrants 524
of adolescents 205
of children previously vaccinated outside India 55
of children with chronic disorders 55
of preterm and low birth weight infants 54
perturbs epidemiology herd
effect 47
immunity 47
post-independent india 15
practiced in India 12
preterm 169
programs 563
strategies for
travelers visiting friends 523
under special circumstances 54
with current licensed rotavirus vaccines 254
Vaccines
antigen
dosage schedule 39
nature of 39
associated
adverse events 79
virus 327
attempts targeting EBV 433
based on HCV DNA 444
carriers 96
cause of
allergic diseases 107
asthma 107
autoimmune diseases 107
characteristics 559
immunogenic efficacy 46
protective efficacy 46
seropositivity 46
seroprotection 46
seroconversion 46
combination 5
complexities of combination 6
cycle 600
delivery systems 484
dendritic cell 7
derived illness 501
development
and manufacturing 541
for human 4t
history of 274
programs 123
discovery and development 476
DNA 7
education center 108
effectiveness and impact in high-and middle-income countries 257
efficacy and formulation 556
epidemiology 139
failure
primary vaccine failure 47
secondary vaccine failure 47
for travelers 523t
for typhoid fever 311
formulations 336
immunity mediated by antibodies 38
immunogenicity and efficacy 243
immunology 25
incidence guidelines 604
induced immunity, mediators of 38
introduction 3
live recombinant 7
monitoring tool 90
policy related issues 578
presentation 561
pricing strategies 544
production and distribution in India 90f
reaction 79
related research 597
research and development 535
risk communication 108
safety and efficacy of combination 5
safety and quality 560
scare-related adverse events 82
scheduling of 57
security 561
storage and handling 332
storage pattern 94f
strain 254
T-cell receptor peptide 7
trials 102
type 39, 58
Vaccinia virus 445
Vaginal and conjunctival infections 214
Vapocoolant 53
Varicelliform rash 324
Vascular endothelial growth factor receptor 405
Vasculitis 291t
Vector-based vaccines 404
Venezuelan hemorrhagic fever 387
Vicarious liability 591
Virosomes 128
Virus
bearing B cell migrates 434
evolution and selective pressure 262
sharing problem involving indonesia 553
shedding and transmission 156
vectors 473
Viscerotropic disease 388
Voluntary code 598
VP7 serotypes 252
W
Walk in coolers 91
Waning of immunity 203
Water bottles to increase cool mass 93f
Weakened immune systems 343
WHO
case definitions for typhoid fever 308t
global influenza surveillance and response network 347
regional measles 280
Wild birds 341
Worldwide malaria cases and mortality 2010 461t
Wound management 190